Ibrexafungerp

(Brexafemme®)

Brexafemme®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormTablet (oral; 150 mg)
Drug ClassTriterpenoid antifungals
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult and post-menarchal pediatric females for vulvovaginal candidiasis (VVC).
  • Indicated for the treatment of adult and post-menarchal pediatric females for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ibrexafungerp (Brexafemme) has demonstrated a superior clinical cure ratio and mycological eradication rate compared to fluconazole/placebo, particularly in cases where the condition is advanced or potentially resistant to first-line treatments.
  • Three studies were reviewed, providing information on the safety and effectiveness of ibrexafungerp for treating vulvovaginal candidiasis (VVC).
  • Ibrexafungerp was found significantly effective against VVC caused by C. albicans, highlighting its efficacy against this common pathogen.
  • Compared to other antifungals like fluconazole, ibrexafungerp showed similar efficacy but with potential advantages due to increased resistance and limited coverage of non-Candida albicans species by fluconazole.
  • Adverse events related to ibrexafungerp were mainly gastrointestinal symptoms, including nausea and diarrhea; however, it remains a well-tolerated option for VVC based on data reviewed.
  • While current data focus largely on adult and post-menarchal pediatric females, indicating broad application for treatment within these groups, there is an emphasized need for additional studies assessing long-term safety and efficacy in special populations, suggesting further research is needed.